Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline ...
Relmada Therapeutics' REL-1017 (esmethadone), and Seelos Therapeutics' SLS-002, an intranasal formulation of racemic ketamine.